Beam Therapeutics selects 60 mg dose for BEAM-302 pivotal trial

March 25, 2026 7:00 AM

Beam Therapeutics Inc. (NASDAQ: BEAM) announced updated clinical data from its Phase 1/2 trial of BEAM-302 for alpha-1 antitrypsin deficiency ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found